Evaluation of the AMICUS RBCx System in Sickle Cell Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2018-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the performance of the AMICUS Red Blood Cell Exchange (RBCx) System (Exchange and Depletion/Exchange procedures) in patients with sickle cell disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients

NCT01736657

Sickle Cell Disease

COMPLETED NA

Stem Cell Gene Therapy for Sickle Cell Disease

NCT02247843

Sickle Cell Disease

COMPLETED PHASE1/PHASE2

Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease

NCT06214845

Acute Chest Syndrome

NOT_YET_RECRUITING NA

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157

Sickle Cell Disease

COMPLETED PHASE4

Allograft for Sickle Cell Disease and Thalassemia

NCT02038478

Sickle Cell Disease and Thalassemia

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of Red Blood Cell Exchange is to remove a patient's red blood cells (RBCs) and replace the blood volume removed with either healthy donor RBCs and/or colloid/crystalloid solutions. Depending on the RF used, the procedure can be considered an RBC Exchange or RBC Depletion/Exchange procedure. The RBC Depletion/Exchange procedure is a modification of the RBC Exchange procedure. The AMICUS RBCx protocol provides the ability to use various RFs including healthy donor RBCs or a combination of fluids, such as saline followed by RBCs. In RBC Exchange and the exchange portion of the RBC Depletion/Exchange procedures, RBC units are used as the RF, while colloid and/or crystalloid solutions are used as the RF in the depletion portion of the RBC Depletion/Exchange procedures. A new operating protocol on the AMICUS Separator that enables the device to perform Red Blood Cell Exchange (RBCx) procedures in accordance with the replacement fluid(s) (RF) prescribed by a physician for patients with sickle cell disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amicus Red Cell Exchange in SCD patients

Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.

Group Type EXPERIMENTAL

Amicus Red Cell Exchange in SCD patients

Intervention Type DEVICE

Each patient will be treated with one RBCx procedure using the AMICUS RBCx System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amicus Red Cell Exchange in SCD patients

Each patient will be treated with one RBCx procedure using the AMICUS RBCx System

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMICUS RBCx System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with documented diagnosis of a type of sickle cell disorder who require RBC Exchange or RBC Depletion/Exchange treatment.
* Medically stable subjects who have been previously treated for sickle cell disease with RBC Exchange or RBC Depletion/Exchange.
* Subjects, or subject's legal representative, who have provided signed informed consent, and assent when applicable, prior to participation.
* Adequate availability of sickle trait negative, leukoreduced, Blood type (ABO) blood group, Rhesus factor D (Rh (D)) compatible, unexpired replacement RBC products.
* Subjects with sufficient vascular access to accommodate the RBCx procedure as determined by the medical staff responsible for obtaining intravenous access.
* Subjects who are able and agree to report adverse events (AEs) during the required reporting period.

Exclusion Criteria

* Procedures that occur during acute hospitalization.
* Procedures prescribed within one week of discharge of a hospitalization.
* Subjects with altered mental status that would prohibit the giving and understanding of informed consent, and assent when applicable, who do not have a legally authorized representative.
* Drug abuse, alcohol abuse, or other factors that in the opinion of the investigator could affect the ability of the subject to comply with the requirements of the protocol.
* Subjects who have experienced a serious adverse event associated with an RBCx procedure in the past.
* In the opinion of the investigator, subjects who have a life expectancy fewer than 30 days.
* Subjects who refuse blood products.
* Subjects who are pregnant.
* Subjects who fail to comply with site requirements for cessation of medication that interfere or increase procedure risk.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No